Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb trial of an optimised formulation of auriclosene for impetigo

Trial Profile

Phase IIb trial of an optimised formulation of auriclosene for impetigo

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2014

At a glance

  • Drugs Auriclosene (Primary)
  • Indications Impetigo
  • Focus Therapeutic Use
  • Sponsors NovaBay Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2014 NovaBay Pharmaceuticals expects to continue with this phase II study if the results of the new formulation from the study in healthy volunteers is supportive of further development.
    • 24 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top